

YEAST: Yet Another Sequential Test

Alexey Kurennoy
alexey.kurennoy@zalando.ie
Zalando
Dublin, Ireland

Majed Dodin
majed.dodin@zalando.de
Zalando
Berlin, Germany

Tural Gurbanov
tural.gurbanov@zalando.de
Zalando
Berlin, Germany

Ana Peleteiro Ramallo
ana.peleteiro.ramallo@zalando.de
Zalando
Berlin, Germany

ABSTRACT

Large-scale randomised experiments have become a standard tool for developing products and improving user experience. To reduce losses from shipping harmful changes experimental results are, in practice, often checked repeatedly, which leads to inflated false alarm rates. To alleviate this problem, one can use sequential testing techniques as they control false discovery rates despite repeated checks. While multiple sequential testing methods exist in the literature, they either restrict the number of interim checks the experimenter can perform or have tuning parameters that require calibration. In this paper, we propose a novel sequential testing method that does not limit the number of interim checks and at the same time does not have any tuning parameters. The proposed method is new and does not stem from existing experiment monitoring procedures. It controls false discovery rates by “inverting” a bound on the threshold crossing probability derived from a classical maximal inequality. We demonstrate both in simulations and using real-world data that the proposed method outperforms current state-of-the-art sequential tests for continuous test monitoring. In addition, we illustrate the method’s effectiveness with a real-world application on a major online fashion platform.

CCS CONCEPTS

• **Mathematics of computing** → **Hypothesis testing and confidence interval computation.**

KEYWORDS

controlled experiments, randomised experiments, A/B testing, test monitoring

ACM Reference Format:

Alexey Kurennoy, Majed Dodin, Tural Gurbanov, and Ana Peleteiro Ramallo. 2024. YEAST: Yet Another Sequential Test. In *Proceedings of the 2024 ACM Conference*. ACM, New York, NY, USA, 12 pages. <https://doi.org/XXX>

1 INTRODUCTION

Online organizations, such as e-commerce platforms, increasingly utilize experimentation approaches to develop products and improve the user experience. While the ability to test changes and iterate on features fast is associated with many benefits, it also substantially increases the risk of exposing users to defective changes,

Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from permissions@acm.org.

XXX '24, Date, 2024, City, Country

© 2024 Copyright held by the owner/author(s). Publication rights licensed to ACM.

ACM ISBN XXX...\$XX.XX

<https://doi.org/XXX>

degrading their experience. Unlike traditional methods (such as the Student t-test) suffering from inflated false detection (Type-I error) rates when applied repeatedly to interim experiment results, sequential testing methods allow repeated checks for significance without inflating the false discovery rate, making it possible to monitor online experiments. In industrial applications, this is crucial as it allows for the early termination of tests that have negative financial impacts, leading to significant cost savings and faster iterations on improvements.

Sequential testing methods can be broadly divided into discrete and continuous. Discrete sequential tests permit only a fixed number of interim checks while continuous methods impose no such limit and allow checking for significance at the experimenter’s will - even after each new observation. In this paper, we mainly focus on continuous sequential tests. We find that the absence of a restriction on the number of interim checks is useful in practice as it avoids a situation where the experimenter and the stakeholders observe a degradation in the metric of interest but have to wait until the next checkpoint before assessing the statistical significance and making decisions.

An important practical challenge associated with currently available state-of-the-art methods for continuous experiment monitoring (such as mSPRT and other martingale methods; see [9, 10, 18] and references therein) is the presence of tuning parameters that need to be calibrated or superimposed.¹ Setting those parameters requires a certain level of expertise that is not always available in applied teams. This motivated us to develop an alternative sequential test which is simpler in that it has no tuning parameters. All of its inputs are straightforward to estimate from pre-experiment data. This new method for continuous test monitoring is the subject of the paper.

Apart from our proposed method, we know only one continuous sequential test that is rigorous (i.e. not a heuristic) and at the same time has no tuning parameters. It is the procedure presented in [22]. However, the method from [22] only supports count-type metrics (such as the number of clicks or purchases) whilst our proposed method can monitor metrics of any type, including real-valued financial metrics such as revenue. We emphasise that this is a non-trivial advancement as the theory presented in [22] fundamentally supports only count-type metrics.

The proposed sequential testing method is novel and based on an alternative theory relative to existing sequential tests.

Our work has both practical and theoretical contributions. On the practical side, we design a sequential test that is flexible (supports unlimited interim checks and arbitrary metrics) and easy to use (has no tuning parameters). At the same time, from the theoretical perspective, this new test is justified by a novel theory that cannot be viewed as an extension of existing frameworks.

¹For example, Φ in [18, Section 3.4], ρ in [10, Proposition 5], and η in [9, Section 4.2].

We extensively validate our approach, showing both in simulations and using real-world data that the proposed method outperforms existing state-of-the-art continuous sequential tests. We share the associated code for greater reproducibility [16].

To summarise, our **main contributions** are:

- We propose a *flexible and easy-to-use* sequential testing procedure. The method supports unlimited interim checks and can monitor metrics of arbitrary types (including real-valued financial metrics such as revenue). Contrary to existing state-of-the-art continuous sequential tests, it has *no tuning parameters*. All of its inputs are straightforward to estimate from pre-experiment data.
- We justify the proposed method with a *novel theory* that is based on the inversion of bounds obtained using (generalised) Levy's inequalities [21, Paragraph 29.1, A] and includes a false detection rate guarantee and a sensitivity (power) statement.
- We compare the proposed method with existing alternatives in an extensive empirical study that includes simulation experiments and assessment based on *real-world data*. We *share the associated code* [16] to improve reproducibility and foster further research.

The remainder of this paper is structured as follows: Section 2 discusses related work. Section 3 introduces the proposed method, explains its derivation, and then presents its formal theory. Section 4 shows how our method can be modified to handle unequal experiment groups or to distribute its sensitivity across the duration of the experiment. In Section 5, we investigate the performance of our sequential test in the framework of a recent simulation study. In Section 6, we assess the correctness of the proposed method using real-world data from a major online fashion platform. Section 7 illustrates the effectiveness of the proposed method with a case study from the fashion platform. Section 8 discusses the limitations of the proposed approach and Section 9 concludes.

2 RELATED WORK

Our work is related to a large literature on sequential decision-making based on decision rules defined via sequences of hypothesis tests, confidence sequences, or sequences of "always-valid" p-values. While the early work in this field was primarily concerned with clinical trials and industrial quality controls [2, 4, 5], more recent work is typically motivated by the sequential nature of online experiments, where users arrive sequentially and generate outcomes that are observed fast relative to the duration of the experiment [10, 13, 17]. Here, the goal of sequential procedures is typically either to reduce the opportunity cost of longer experiments, e.g. in the context of best-arm identification in multi-armed bandit problems [11, 12, 14, 35], or risk management, i.e. the quick detection of harmful treatments [9, 20]. Our work is primarily concerned with the latter and this section focuses on the two dominant approaches underlying the monitoring methods used by large online organizations [26].

2.1 Sequential Probability Ratio and Martingale Methods

Building on the seminal work of Wald [31] and Doob [6], most modern sequential procedures are based on maximal inequalities for appropriately constructed martingales that provide time-uniform statistical guarantees. While Wald's original sequential probability ratio test (SPRT) was developed from scratch, its construction is essentially of this "martingale-type". The SPRT sequentially evaluates the likelihood ratio test statistic at sample size n for the null $H_0 : \theta = \theta_0$ against the single point alternative $H_1 : \theta = \theta_1$ until either one of two bounds are crossed and rejects or fails to reject the null accordingly. While the SPRT terminates for finite n , the corresponding confidence sequence does not shrink towards zero as $n \rightarrow \infty$ [32] and requires the specification of a single point alternative, making it unsuitable for general purpose monitoring of experiments. This shortcoming motivates likelihood ratio based procedures that rely on the methods of mixtures, which replace the single point alternative with a composite hypothesis and the likelihood ratio with a mixture that is still a martingale under the null [25]. These mixture sequential probability ratio tests (mSPRT) control false discovery rates at any point in time but require the specification of a mixing distribution. Methods to continuously monitor experiments based on the mSPRT, as well as related but more involved methods constructed through other martingales, are routinely used in large scale online organizations. [3, 9, 10, 13, 18, 19].

2.2 Group Sequential Methods

A conceptually different approach is followed by methods based on group sequential tests (GST) [8, 23, 24, 28]. GST methods rely on (asymptotic) characterizations of the joint distribution of a vector of test statistics across increments of data, which permits the computation of sequential boundaries that uniformly control the false discovery rate via multivariate (numerical) integration. While GST methods also do not require to specify the timing of tests in advance, they require the specification of a function ("alpha spending function") that governs the sensitivity across tests given a pre-specified maximum sample size. As a consequence, GSTs, while typically providing tighter confidence sequences than mSPRT-based methods, do not strictly speaking support the continuous monitoring of tests.

3 YEAST: YET ANOTHER SEQUENTIAL TEST

In this section, we present a novel, alternative sequential testing method proposed in this paper.

3.1 Problem Setup and Notation

Suppose we are conducting a randomised online experiment and have a certain metric of interest. For ease of exposition let us assume that the experiment has only two groups (control and treatment). We explain how to handle experiments with multiple treatment groups in Section 4 below. We want to constantly track the metric of interest and have a tool to check if the difference between the groups is at any point large enough to conclude that the treatment has an impact on the metric. The tool must have good control of the false detection rate despite the repeated checks. In other words,

it must allow peeking into the interim results of the experiment without inflating the false detection rate.

To develop a tool satisfying the above requirement, we consider the difference S in the total value of the metric of interest accumulated by the control ($W = 0$) and the treatment ($W = 1$) groups. Typically, this difference S can be represented as a sum of increments over a stream of events. For example, if the metric of interest is revenue then the tracked difference S can be decomposed into the sum of order values over checkout events where the order value is taken with a positive sign if it comes from the control group and with a negative sign if it comes from the treatment arm. Mathematically, the increments can be written as

$$X_i = (1 - 2W_i) Y_i, \quad (1)$$

where Y_i is the value or outcome associated with the i -th event (such as the order value in the example above) and W_i is the event assignment indicator (it equals 0 if the event was generated by a subject from the control group and 1 if its subject belongs to the treatment group). With this notation at hand, the difference in the metric of interest after observing n events can be written as the running sum

$$S_n = \sum_{i=1}^n X_i, \quad n \geq 1, \quad (2)$$

as illustrated in the example data set displayed in Table 1.

Table 1: An Example of Experiment Data

i	timestamp	group	Y	X	S
1	2023-08-01 12:00:00	control	175.0	175.0	175.0
2	2023-08-01 12:00:02	treatment	35.5	-35.5	139.5
3	2023-08-01 12:00:05	treatment	20.0	-20.0	119.5
4	2023-08-01 12:00:10	control	100.0	100.0	219.5
...

So far we have used revenue monitoring as an example but one can think of examples from other domains such as

- video streaming (metric: hours streamed; the events are user sessions; the event value is the total duration of videos streamed within the session),
- online advertisement (metric: number of clicks; the events are clicks; the event value is 1),
- medical drug trial (metric: number of cases of side-effects; the events are incoming patients; the event value is the indicator of side-effect presence after taking the drug),
- online subscription services (metric: number of new users who convert into a paid subscription; the events are newly acquired users; the event value is the indicator of subscribing),
- banking (metric: total transaction fee; the events are transactions; the event value is fee amount),

and others.

3.2 Assumptions and the Null Hypothesis

We will now state and discuss our assumptions and the null hypothesis.

Assumption 1 (Random Subject Assignment) *The subjects are assigned to the control or treatment uniformly at random and with equal probability.*

We assume that the assignment is balanced only to derive a base version of our proposed monitoring procedure. It is then straightforward to modify this base version to handle unequal groups. We explain how to do this in Section 4 below.

We work with the following null hypothesis.

\mathbf{H}_0 : *the treatment does not affect either the event outcome distribution or the frequency of events, so that*

- (a) the event outcomes and the assignment indicators are independent from each other, i. e.

$$\{Y_1, Y_2, \dots\} \perp\!\!\!\perp \{W_1, W_2, \dots\}, \quad (3)$$

- (b) and the frequency of events in each group is the same, implying (under Assumption 1) that

$$\Pr\{W_i = 1\} = 0.5 \quad \forall i \geq 1. \quad (4)$$

In the setting of this paper, it is important to distinguish between subjects (such as users) and events generated by subjects (such as orders). Throughout the paper, we work with variables associated with events and not subjects. For example, Y_i , $i \geq 1$, are event outcomes and W_i , $i \geq 1$, are event assignment indicators. One implication of this is that even though the subjects are assigned to one of the two groups independently at random, the variables associated with individual events can be dependent (as some of them can be generated by the same user). Therefore, in our main theory (Theorems 1 and 2), we allow the event outcomes Y_i , $i \geq 1$, to be dependent and, likewise for the event assignment indicators W_i , $i \geq 1$. The part (a) of the null hypothesis stated above only assumes that the two sets of variables ($\{Y_1, Y_2, \dots\}$ and $\{W_1, W_2, \dots\}$) are independent from each other but the variables within each of the two sets are allowed to be dependent. Note that we also do not require Y_i , $i \geq 1$, to be identically distributed.

The null hypothesis stated above exhibits the difference between our setup and the classical testing for a zero average treatment effect. Specifically,

- our testing procedure acts on the level of events generated by experiment subjects and not the experiment subjects themselves (for example, orders and not customers);
- we assume that under the null hypothesis, the treatment does not affect the “event generation process” in any way.

In the revenue monitoring example, the latter implies that both the frequency of orders and the order value distribution stay the same in both groups under the null. We discuss the limitations of the considered setup in Section 8.

The approach described so far allows us to derive a simple but effective sequential testing procedure we present next.

3.3 Proposed Sequential Testing Method

The proposed monitoring method consists of tracking the difference in the metric of interest between the experiment groups and (continuously) comparing it with a constant (alerting) boundary. Whenever the boundary is crossed, we can conclude (with a predefined significance level α) that the treatment has an impact on the metric.

The procedure requires setting the maximum number of events to be observed during the monitoring period that we denote by N . In other words, the boundary is computed assuming that the monitoring will not continue after N events have been collected. See Section 3.4 for how to set N in practice.

The proposed method has only one other parameter that needs to be estimated beforehand - the (scaled) variance of the difference in the metric of interest at the end of monitoring, $V_N = \text{var}(S_N)/N$. The estimator of V_N needs to be consistent under the null hypothesis. Given the estimate \hat{V}_N (computed by such an estimator), the alerting boundary is set to

$$b^* = z_{1-\alpha/2} \cdot \sqrt{N\hat{V}_N}, \quad (5)$$

where $z_{1-\alpha/2}$ is the quantile of the standard normal distribution of level $1 - \alpha/2$. The proposed simple sequential test proceeds by tracking S_n and comparing it against b^* .

3.3.1 Informal Derivation of the Proposed Method. The derivation of the alerting boundary (5) follows two steps. First, we use Levy's inequality [21, Paragraph 29.1, A] to bound the false detection rate by the probability that the tracked sum exceeds the threshold at the end of monitoring, i. e.

$$FDR = \Pr \left\{ \max_{n=1}^N S_n > b \right\} \leq 2 \Pr \{S_N > b\}.$$

In the second step we use the Central Limit Theorem to approximate the latter probability,

$$\Pr \{S_N > b\} \approx 1 - \Phi \left(\frac{b}{\sqrt{\text{var}(S_N)}} \right) = 1 - \Phi \left(\frac{b}{\sqrt{NV_N}} \right),$$

where Φ denotes the CDF of the standard normal distribution. Then by setting the threshold b to $z_{1-\alpha/2} \cdot \sqrt{NV_N}$ (cf. (5)), we ensure that the false detection rate is under control, i. e. $FDR \lesssim \alpha$. This is formalised in Theorem 1 below.

The proposed testing procedure is defined in Algorithm 1 and will be referred to as *YEAST* (from *YEt Another Sequential Test*). The estimation of V_N is discussed in Section 3.4 below.

Algorithm 1 YEAST

Require: N, \hat{V}_N
 $b^* \leftarrow z_{1-\alpha/2} \sqrt{N\hat{V}_N}$
for $n = 1, \dots, N$ **do**
 if $S_n > b^*$ **then**
 flag significance
 end if
end for

For a two-sided test, we track $|S_n|$ and compare it against

$$b_{2\text{-sided}}^* = z_{1-\alpha/4} \cdot \sqrt{N\hat{V}_N}, \quad (6)$$

where $z_{1-\alpha/4}$ is the quantile of the standard normal distribution of level $1 - \alpha/4$. Mind that differently from the non-sequential testing, the significance level α needs to be divided by 2 for the one-sided test and by 4 for the two-sided test. This is due to the factor of two in the right-hand side of inequalities (14) and (15) below.

3.4 Setting the Input Parameters

As was described in the previous subsection, the computation of the alerting boundary of the proposed sequential testing procedure requires two inputs: the number of events N to be observed during the monitoring and an estimate \hat{V}_N of the (scaled) variance of the tracked metric difference at the end of the monitoring. In this subsection, we discuss how to provide those inputs in practice.

To set N , we estimate the expected number of events to be collected over the experiment time frame. In the simplest form, this can amount to setting N to the number of events observed in a pre-experiment period of the same duration as the experiment we want to monitor.

For variance estimation, we suggest using pre-experiment data as well. Obtaining an accurate estimate this way requires the pre-experiment period to be representative of the experiment time. However, in cases where this cannot be assumed, the validity of fixed-duration randomised experiments is questionable in principle (as the effects measured during such experiments may not generalise beyond their time frames). So in the context of A/B testing, this is a natural assumption.

As was noted in Section 3.2, the event outcomes $Y_i, i \geq 1$, can be dependent because some of the events are generated by the same user. The same holds for the event assignment indicators $W_i, i \geq 1$. Consequently, the increments $X_i, i \geq 1$, of the monitored trajectory can be serially correlated in which case the variance $\text{var}(S_N)$ does not equal the sum of variances $\text{var}(X_i)$. The serial correlation of the increments has a clustered nature in this case because variables corresponding to different users are independent due to random assignment. Therefore, we propose to use an estimator that is robust to clustered serial correlation [1] to estimate V_N . Implementations of such estimators are readily available, for example as part of the sandwich package in R [36, 37] (see function `vcovCL`). The cluster variable in this case is the user identifier. As we will show in our experiments with real-world data in Section 6, the use of a robust (clustered) variance estimator (instead of the simple sum of $\text{var}(X_i)$) can be utterly important for effective control of the false detection rate.

Note that the inputs of the proposed method (N and V_N) can be directly estimated from pre-experiment data and setting them does not require tuning or leveraging expert knowledge. The absence of tuning parameters makes the proposed Algorithm 1 (YEAST) easy to use.

3.5 Formal Statements

In this subsection, we will justify the correctness of the proposed testing procedure. This includes a statement demonstrating that the proposed method controls the false detection rate (Theorem 1), and a statement showing that the power of the method is asymptotically one (Theorem 2).

In the formal statements below, $(\Omega, \mathcal{F}, \Pr)$ is a probability space and \mathbb{R} stands for the set of real numbers. As before, Φ denotes the CDF of the standard normal distribution. The proofs of the statements can be found in Appendix A.

The first theorem (see below) states that when the treatment has no actual impact, detections occur sufficiently rarely. Its proof (see Appendix A) has two steps. First, we bound the chance of

“crossing the threshold” at any moment during the monitoring by twice the probability of crossing it at the last moment. Secondly, we approximate the latter probability with the help of the Central Limit Theorem (noting that the tracked difference at the end of monitoring is the sum of a large number of increments). This allows us to construct the threshold appropriately, ensuring that the method’s false detection rate is small enough.

THEOREM 1 (FALSE DETECTION RATE CONTROL). *Let $Y_i: \Omega \mapsto \mathbb{R}$ and $W_i: \Omega \mapsto \{0, 1\}$, $i = 1, \dots, N$, be random variables and let S_n , $n \geq 1$, be the running sum defined by (1)–(2). Suppose that Assumption 1 and the null hypothesis (3)–(4) hold and that a version of the Central Limit Theorem is valid for the sequence of random variables X_1, X_2, \dots defined by (1). Assume that $\text{var}(S_N) > 0$ for all $N \geq 1$ and set $V_N := \text{var}(S_N)/N$.*

Then for any $\alpha \in [0, 1]$ and any $\varepsilon > 0$ there exists $N_{\alpha, \varepsilon}$ such that for all $N \geq N_{\alpha, \varepsilon}$ we have

$$\Pr \left\{ \max_{n=1}^N S_n > z_{1-\alpha/2} \sqrt{NV_N} \right\} \leq \alpha + \varepsilon,$$

where $z_{1-\alpha/2}$ is the quantile of the standard normal distribution of level $1 - \alpha/2$.

Note that we deliberately do not spell specific conditions ensuring that the central limit properties hold for the sequence of increments $\{X_i\}$. Multiple sets of such conditions exist. A good overview of them can be found in [34, Chapter V].

Our second theorem claims that when the treatment has an effect, its detection can be made as certain as desired if we monitor for sufficiently long. The idea of its proof is to note that the probability of detecting the effect at any moment during the monitoring is at least as high as the probability of detecting it at the very end. Then we leverage the Central Limit Theorem to show that (when the treatment effect exists) the latter probability approaches 1 as the monitoring duration increases, completing the proof (see Appendix A for details).

THEOREM 2 (POWER). *Let $Y_i: \Omega \mapsto \mathbb{R}$ and $W_i: \Omega \mapsto \{0, 1\}$, $i = 1, \dots, N$, be random variables, and let S_n , $n \geq 1$, be the running sum defined by (1)–(2). Suppose that Assumption 1 holds and a version of the Central Limit Theorem is valid for the sequence of random variables X_1, X_2, \dots defined by (1). Assume that $\text{var}(S_N) > 0$ for all $N \geq 1$ and that the set of variables $V_N = \text{var}(S_N)/N$, $N \geq 1$, is stochastically bounded. Finally, let $E[X_i] = \mu_i > 0$ (implying that the null hypothesis (3)–(4) is violated).*

Then

$$\Pr \left\{ \max_{n=1}^N S_n > z_{1-\alpha/2} \sqrt{NV_N} \right\} \rightarrow 1 \quad \text{as } N \rightarrow \infty.$$

Similar FDR control and “power” theorems hold for the two-sided version of our method and can be obtained in full analogy to the above statements.

4 EXTENSIONS

4.1 Unequal Groups And Multiple Treatment Groups

For randomised experiments with unequal groups, one can down-sample the larger group when computing the cumulative KPI difference S_n and then apply the monitoring procedure (Algorithm 1).

It is important to note that the down-sampling must be done with respect to subjects and not events (e. g. following the e-commerce example, on the level of users, not orders). The reason for that is that the bigger group can be causing harm by making subjects generate fewer events on average, and we want the monitoring to be sensitive to such situations.

If there are multiple treatment groups, one can monitor each treatment separately applying the procedure developed in Section 3 to each treatment-control pair (with an appropriately reduced significance level to correct for multiple comparisons). On the other hand, if the purpose of monitoring is to stop early when the experiment as a whole is causing harm, we recommend handling all of the treatment groups collectively (as if it was a single group) and then down-sampling it as in the case of unequal groups.

We also considered reweighting instead of downsampling (based on the known ratio between the group sizes). Yet, extending the theory to the weighted sum case turns out to be challenging for now. The reason is that reweighting sets the mean of the sum to zero but is not guaranteed to make its median zero as needed to bound the crossing probability in our case. We plan to revisit this in our future work.

4.2 Progressive Thresholds

The method proposed in Section 3 gives a constant significance boundary. Graphically, it corresponds to a horizontal line (see Figure 2 below for an example). If at any moment during the experiment, the cumulative difference in the metric of interest between the control and treatment (i.e. the observed loss) crosses this line, we consider it as evidence that the treatment is causing harm. As we will show in this section, a similar idea can be used to produce a sequence of significance thresholds, increasing in magnitude. This way, we can maintain a tighter “limit” on the observed loss in the early days of the experiment and guard against particularly harmful treatments more effectively. Such a sequence of thresholds visually forms a staircase instead of a line (Figure 2).

Only in this section, we will maintain one extra assumption (in addition to Assumption 1 stated in Section 3.2).

Assumption 2 (Independence of Increments) *The increments $X_i = (1 - 2W_i)Y_i$, $i \geq 1$, are independent.*

This assumption generally holds when all subjects generate only one event as in the examples of a drug trial and online subscription services mentioned at the end of Section 3.1 or when the random assignment is done on the event level (e. g. when the events are sessions and we randomise per session).

To obtain progressive thresholds, let us divide the experiment timeline into K periods (e.g. days) and suppose we want to set K alerting thresholds b_1, \dots, b_K . Let N_k be the sample size (number of events) in period k . Furthermore, let S_n be the difference in the total metric value between the control and treatment as in (2). Finally, suppose that M_k is the maximum value of S_n in period k . With this notation at hand, we can write the false detection probability as follows.

$$\begin{aligned} FDR = & \Pr\{M_1 > b_1\} + \Pr\{M_1 \leq b_1, M_2 > b_2\} + \\ & + \dots + \Pr\{M_1 \leq b_1, \dots, M_{K-1} \leq b_{K-1}, M_K > b_K\}. \end{aligned} \quad (7)$$

According to the theory from Section 3 (see Lemma 2), the first term in the above sum can be bounded by $2\Pr\{S_{N_1} \geq b_1\}$ which, under the null hypothesis, can be approximated with $2\left(1 - \Phi\left(\frac{b_1}{\sqrt{U_1}}\right)\right)$, where U_1 denotes $\text{var}(S_{N_1})$ and, as before, Φ stands for the CDF of the standard normal distribution. Let us now consider the remaining terms.

For any $k = 1, \dots, K$ we can write

$$\begin{aligned} & \Pr\{M_1 \leq b_1, \dots, M_{k-1} \leq b_{k-1}, M_k > b_k\} \\ & \leq \Pr\{S_{N_1+\dots+N_{k-1}} \leq b_{k-1}, M_k > b_k\} \stackrel{\text{Assumption 2}}{=} \\ & = \int_{-\infty}^{b_{k-1}} \left[\Pr\left\{ \max_{\ell=1, \dots, N_k} \sum_{i=1}^{\ell} X_{N_1+\dots+N_{k-1}+i} \geq b_k - x \right\} \right. \\ & \quad \left. \times f_{S_{N_1+\dots+N_{k-1}}}(x) \right] dx, \end{aligned}$$

where $f_{S_{N_1+\dots+N_{k-1}}}$ is the density of $S_{N_1+\dots+N_{k-1}}$. As in Theorem 1, we assume that a Central Limit Theorem holds for the sequence $\{X_i\}$. Then, under the null hypothesis, $f_{S_{N_1+\dots+N_{k-1}}}$ can be approximated by the density of a centred normal variable with variance $U_{k-1} = \text{var}(S_{N_1+\dots+N_{k-1}})$. At the same time, by applying Lemma 2, we have

$$\begin{aligned} & \Pr\left\{ \max_{\ell=1, \dots, N_k} \sum_{i=1}^{\ell} X_{N_1+\dots+N_{k-1}+i} > b_k - x \right\} \\ & \leq 2\Pr\left\{ \sum_{i=1}^{N_k} X_{N_1+\dots+N_{k-1}+i} \geq b_k - x \right\} \approx 2\left(1 - \Phi\left(\frac{b_k - x}{\sqrt{u_k}}\right)\right), \end{aligned}$$

where u_k denotes the variance of $\sum_{i=1}^{N_k} X_{N_1+\dots+N_{k-1}+i}$. Therefore, $P\{M_1 \leq b_1, \dots, M_{k-1} \leq b_{k-1}, M_k > b_k\}$ can be (approximately) bounded by

$$I_k = 2 \int_{-\infty}^{b_{k-1}} \left[\left(1 - \Phi\left(\frac{b_k - x}{\sqrt{u_k}}\right)\right) \varphi\left(\frac{x}{\sqrt{U_{k-1}}}\right) \left(\sqrt{U_{k-1}}\right)^{-1} \right] dx,$$

where φ denotes the density of a standard normal random variable. Setting $Z_k = \Phi\left(\frac{b_{k-1}}{\sqrt{U_{k-1}}}\right)$, we can further rewrite it like this:

$$I_k = 2Z_k(1 - J_k), \quad (8)$$

where

$$J_k = \int_{-\infty}^{b_{k-1}} \left[\Phi\left(\frac{b_k - x}{\sqrt{u_k}}\right) \varphi\left(\frac{x}{\sqrt{U_{k-1}}}\right) \left(Z_k \sqrt{U_{k-1}}\right)^{-1} \right] dx. \quad (9)$$

Note that the integral J_k is a convolution between a centred normal and a truncated normal distribution (evaluated at b_k). To compute this integral one can apply methods listed in [7], for example, [15, Formula 2.4].

In summary, from (7)–(9), we have that for any given set of thresholds b_1, \dots, b_K , the associated false detection rate can be (approximately) bounded by

$$\text{FDRBound} = 2\left(1 - \Phi\left(\frac{b_1}{\sqrt{U_1}}\right) + \sum_{k=2}^K Z_k(1 - J_k)\right).$$

Having the (approximate) FDR bound (4.2), one can find a set of thresholds such that the bound is below the desired significance level α . For example, the thresholds can be initialised with $b_k^0 = z_{1-\alpha/2} \cdot \sqrt{\hat{U}_k}$, $k = 1, \dots, K$, where \hat{U}_k is an estimate of $\text{var}(S_{N_1+\dots+N_k})$ and then multiplied by $(1 + \varepsilon)$ (where ε is a chosen small enough number) until the FDR bound (4.2) gets below α . This procedure is formally described in Algorithm 2.

Algorithm 2 “Staircase” Significance Boundary Computation

Require: $K, N_1, \dots, N_K, \hat{U}_1, \dots, \hat{U}_K, \hat{u}_1, \dots, \hat{u}_K, \varepsilon > 0$

Ensure: $b_1^*, \dots, b_K^* : \text{FDRBound}(b_1^*, \dots, b_K^*) \leq \alpha$

for $k=1, \dots, K$ **do**

$b_k^* \leftarrow z_{1-\alpha/2} \sqrt{\hat{U}_k}$

end for

while $\text{FDRBound}(b_1^*, \dots, b_K^*) > \alpha$ **do**

for $k = 1, \dots, K$ **do**

$b_k^* \leftarrow (1 + \varepsilon)b_k^*$

end for

end while

As was mentioned before, maintaining a sequence of thresholds allows having a tighter limit on the observed loss in the early days of the experiment. This makes the monitoring more effective at reducing risks associated with particularly harmful treatments but comes at the cost of having a looser significance boundary closer to the end of the test.

The procedure developed in this section resembles the so-called alpha-spending approach [8, 23, 24, 28] but, importantly, allows for continuous monitoring rather than a discrete number of checks. In what follows, we will refer to it as *pYEAST*.

5 SIMULATION EXPERIMENTS

When designing our simulation experiments, we sought to extend an existing setup that has already been reviewed by the relevant community of researchers and practitioners. Hence, our simulation setting follows a recent study [26] and the implementation is based on the associated code [27] which we extended with the proposed methods from Sections 3 and 4.2 above.

In particular, as in [27], we generate N observations from control, Y_i^c , $i = 1, \dots, N$, and N observations from treatment, Y_i^t , with N set to 500. Both Y_i^c and Y_i^t are generated as IID random variables. The effect size (on the mean) took values 0.0, 0.1, 0.2, 0.3, and 0.4. The X_i variables (increments in the metric difference between the two groups) were computed as $X_i = Y_i^c - Y_i^t$, $i = 1, \dots, N$.

We conducted two simulation experiments. The first (main) experiment repeats the simulation study from [26] but adds the methods proposed in Section 3 and Section 4.2 to the evaluation. In the second set of simulations, we explored the behaviour of the compared methods when the increments are non-normal.

In all of the experiments, the target significance level was set to 5% and the number of replications was set to 100,000.

The simulation code for this paper can be found in the associated git repository [16].

5.1 Main Simulation Experiment

In this experiment, the observations Y_i^c and Y_i^t were drawn from normal distributions with parameters $(1, 1)$ and $(1 + \xi, 1)$, respectively. The effect size ξ took values 0.0, 0.1, 0.2, 0.3, and 0.4. The seed of the random generator was set to 8163 (as in [26, 27]).

Below we present the list of methods we compared.

YEAST The simple sequential method using a constant significance boundary (5) as proposed in Section 3.

pYEAST The method using a staircase significance boundary as proposed in Section 4.2 (see Algorithm 2). We set K (number of periods) to 7 and 14 and denote the respective instances of the method by pYEAST7 and pYEAST14.

mSPRT The mixture sequential probability ratio test [20, 25]. We set the tuning parameter of the method to 11, 25, and 100 and denote the corresponding versions as mSRTphi11, mSRTphi25, and mSRTphi50.

GAVI The generalization of the always valid inference, as proposed in [10]. As in [26], we set the numerator of parameter ρ of the method to 250, 500, and 750 and denote the corresponding instances of the method by GAVI250, GAVI500, and GAVI750, respectively.

CAA The corrected-alpha approach [29].

Bonferroni A naive approach using Bonferroni corrections.

All of the compared methods were employed in the continuous monitoring mode meaning that the check for significance was performed after each observation. In Appendix B we report additional evaluation results for the case where the methods are used in the "discrete mode" (i. e. with a fixed number of interim significance checks).

For each experimental setting, we conducted 100,000 replications. Each replication can result in a detection or no-detection. A detection occurs when the respective test flags significance (at any point of the monitoring process). We compute the share of replications where a detection occurs. When the treatment does not have an effect this share is the so-called (empirical) false detection rate (or, synonymously, false positive rate, type-I error, or test "size"). In settings where the treatment has an effect, this share is the (empirical) power. We report the measured false detection rate and power in Table 2. Note that we do not report power for those methods that have an inflated false detection rate. Otherwise, the comparison would not be fair because one can generally obtain extra power by inflating the false detection rate. We also omit the column corresponding to the effect size of 0.4 because all methods under comparison had a power very close to one in that case. The method with the highest power is shown in bold.

One can see from the table that the procedure proposed in Section 3 (Algorithm 1, YEAST) demonstrated the highest power among the continuous monitoring approaches that do not inflate the false detection rate. It means that while it kept the false positive rate under control when there was no treatment effect, YEAST had the highest sensitivity in simulations where the treatment had an effect on the metric of interest. The "staircase" extension of the proposed method developed in Section 4.2 (pYEAST7 and pYEAST14) came as a runner-up: it also kept the false positive rate below the pre-specified level and had the second and third highest power (after YEAST).

Table 2: Simulation Experiment: False Detection Rate and Power

	effect size	0.0	0.1	0.2	0.3
	method				
1	YEAST	0.05	0.44	0.92	1.00
2	pYEAST7	0.03	0.30	0.82	0.99
3	pYEAST14	0.03	0.25	0.78	0.99
4	mSPRTphi100	0.02	0.22	0.76	0.99
5	mSPRTphi11	0.03	0.22	0.73	0.98
6	mSPRTphi25	0.03	0.24	0.76	0.99
7	GAVI250	0.02	0.24	0.76	0.99
8	GAVI500	0.02	0.23	0.76	0.99
9	GAVI750	0.01	0.21	0.75	0.99
10	CAA	0.07	-	-	-
11	Bonferroni	0.00	0.04	0.40	0.90

The main benefit of sequential testing is the ability to stop the experiment early (once significance is flagged upon one of the interim checks). This allows saving time and, in case the treatment is harmful, reduce financial losses. Thus, the amount of savings that is generated by a sequential test on average is another important metric and we report it in Table 3. The savings are measured as follows: if a method identified the effect after the arrival of 10% of the total number of observations, the associated sample (or, equivalently, time) savings would be 90%.

Among the compared methods, a variation of our proposed method with progressive thresholds, pYEAST7, generated the largest savings on average for most of the effect sizes we experimented with. Overall, pYEAST generated higher savings than YEAST, which is expected since the purpose of having a staircase boundary instead of a constant significance threshold was to be able to detect large treatment effects faster. Note that pYEAST14 performed very closely to pYEAST7 in terms of the generated savings, so the results were not sensitive to the choice of the number of periods (or boundary "stairs", K) in the pYEAST method.

Table 3: Simulation Experiment: Sample/Time Savings

	effect size	0.1	0.2	0.3	0.4
	method				
1	YEAST	0.13	0.39	0.58	0.69
2	pYEAST7	0.14	0.44	0.69	0.80
3	pYEAST14	0.12	0.41	0.68	0.80
4	mSPRTphi100	0.09	0.35	0.62	0.75
5	mSPRTphi11	0.12	0.41	0.68	0.82
6	mSPRTphi25	0.12	0.41	0.68	0.81
7	GAVI250	0.12	0.40	0.67	0.80
8	GAVI500	0.10	0.37	0.63	0.77
9	GAVI750	0.08	0.34	0.60	0.74
10	Bonferroni	0.02	0.19	0.45	0.67

5.2 Non-Normal Data

The derivation of the methods proposed in Section 3 and 4.2 involves the application of the Central Limit Theorem to sums of X_i (increments in the metric difference between the two groups). For a fixed sample size, the quality of the normal approximation depends on the distribution of X_i . In this section, we explore the performance of the sequential testing methods proposed in Sections 3 and 4.2 (YEAST, pYEAST7, and pYEAST14) in situations where the distribution of Y_i^c and Y_i^t is not normal. Specifically, we used two alternative distributions: Student's t which has heavier tails than the normal distribution and Gamma which is asymmetric. Student's t distribution had 3 degrees of freedom and was shifted by $\sqrt{3}$ for the control and by $\sqrt{3}(1 + \xi)$ for the treatment. The shifting was done to maintain the same coefficient of variation as in Section 5.1). The Gamma distribution had its shape parameter set to 1.0. The scale parameter equaled 2 for the control and $2(1 + \xi)$ for the treatment. The effect size ξ took the same values as in the main experiment: $\xi = 0.0, 0.1, 0.2, 0.3, 0.4$. The random seed was set to 2023 for the simulations with the Student's t distribution and to 2024 for the simulations with the Gamma distribution. The two seeds were different to avoid dependence across the two sets of simulations.

The results are depicted in Figure 1. The first data point on each line corresponds to the case of no treatment effect and therefore represents the false detection rate. The remaining points represent the power for different treatment effect sizes. Similarly to the normal case, the CAA method was the only one with an inflated false detection rate (and we omit it from the plot for that reason). Among the methods that did not have an inflated false positive rate, the method proposed in Section 3, YEAST, performed best with a considerably higher power curve (both for the Gamma and the Student's t distribution cases).

6 VALIDATION USING REAL-WORLD DATA


We further validated our proposed approach using real data from a major e-commerce platform. The data consisted of checkout events (placed orders) from 22 weeks. It was split into periods of two weeks, which is a typical A/B-experiment duration on the e-commerce platform. We used all but the first two-week periods for validation.

This data naturally contained outliers (such as resellers that have a huge purchase volume and can easily skew the monitored metric difference in favour of one of the groups). To remove them, we applied revenue capping at the 99.9th percentile of the total revenue generated by a customer. For capping in each validation period, the percentile was computed using the preceding two-week period. The capping was applied progressively as follows: a given customer was only monitored while his/her revenue stayed within the cap and all subsequent events *from that customer* were discarded.

For each validation period, we randomly assigned users to control and treatment 10,000 times², computed the cumulative difference in the revenue between control and treatment for each assignment replication, applied the sequential tests to monitor the cumulative difference, and measured the frequency of detections over the replications. We then pooled the measurements from the

²The random seed for replicating the assignments was set to $2024 + i$, where i is the number of the respective two-week validation period, $i = 1, \dots, 10$.

Figure 1: Power Curves (under non-normal increment distributions)



10 validation periods and computed the detection rate from the resulting 100,000 data points. Since no actual treatment was applied to the replicated treatment groups, the null hypothesis was true, and the computed rates were false detection rates. They are reported in Table 4 below. In all cases, the width of the confidence interval for the false detection rate was an order of magnitude smaller than the false detection rate itself and hence we omitted the confidence intervals from the table so as not to clutter it.

When applying the sequential tests to the data from a given period, the estimation of input parameters was conducted on the preceding two-week period. As was mentioned in Section 3.1, we employed the sequential tests with two different variance estimates. One of the two assumed that the increments X_i of the monitored difference-in-sum are independent. The other was an estimator robust to cluster serial correlation, that is - to the correlation between increments corresponding to the same user in our case. The results corresponding to the use of the two estimators are reported in columns 'non-robust' and 'robust' of Table 4, respectively.³

Two observations from our experiment with the real-world data are in order. First, the proposed method (YEAST) demonstrated the best result among the compared methods (i. e. its false detection rate was closest to the nominal significance level) when using the robust variance estimator. Second, all the methods had a considerably inflated false detection rate when using the non-robust estimator. The latter highlights the importance of accounting for the correlation in the events generated by the same user when estimating the variance.

³We used the `vcovCL` function of the `sandwich` R package to compute the robust variance estimate. To reduce the sparsity in the time dimension, we summed the data (revenue increments) by user-hour before computing the estimator. We also used downsampling (in the user dimension) to speed up the computation of the estimate.

The code implementing our experiment with the real-world data is openly available in the git repository of the paper [16].

Table 4: Validation Using Real-World Data: False Detection Rate

	variance estimate method	robust	non-robust
1	YEAST	0.04	0.12
2	pYEAST14	0.02	0.09
3	mSPRT100	0.03	0.16
4	mSPRT011	0.02	0.13
5	mSPRT025	0.02	0.14
6	GAVI250	0.02	0.15
7	GAVI500	0.03	0.16
8	GAVI750	0.03	0.16
9	CAA	0.07	0.15

7 REAL-WORLD APPLICATION

The proposed sequential testing method was implemented by a major ecommerce platform and have been used there as a standard tool to monitor A/B tests in production. We picked two of those tests as an illustration and will present them in this section.

When monitoring live online experiments, we use the progressive variant of the method (pSST) with the number of periods set to the number of days over which the experiment is to run. Our main goal is to mitigate the risk of financial losses and therefore we use the one-sided test (to increase the power at detecting performance degradations). The significance level is set to 5%.


The trajectory of the difference in the Gross Merchandise Value (GMV) between treatment and control in the two examples is shown in Figure 2 (blue solid line). The red line shows the pSST thresholds (i.e. the alerting boundary). We also plot the SST boundary using a dashed red line for comparison.

Both of the two experiments were scheduled to run for 2 weeks. In the first experiment (see the upper plot), the monitoring detected a performance degradation on day 4 and the test was stopped early, which allowed us to save revenue and iterate faster. The lower plot corresponds to the second experiment in which no detection occurred. The plot shows only the first few days of the test but it was run for the full duration of 14 days and its treatment improved engagement metrics without harming the financials (as concluded by the post-analysis). The second experiment is particularly interesting as its GMV trajectory was tracking below zero close to the beginning of the test. It showcases the importance of using rigorous monitoring procedures as naive monitoring could have raised concerns over the observed loss at the start of the test and could potentially lead to the test being stopped and unfairly deemed unsuccessful. In this example, the use of our monitoring method helped avoid concerns and make the right decision to continue the test.

8 LIMITATIONS

We have seen in Sections 5 and 6 that despite its simplicity, the proposed monitoring procedure is very effective at controlling the

Figure 2: Monitoring Examples



type-I error and has a high power. Yet there are scenarios where the underlying null hypothesis of no effect on the data generation process is too strong, potentially leading to some “undesirable sensitivity”. In other words, sometimes the treatment can alter the data generation process but have a neutral average effect on the metric of interest. We can think of (at least) two such scenarios.

Situations where the treatment brings multiple changes to the data generation process and those changes counter-balance each other leading to a neutral average effect on the metric. For example, the treatment can make users place fewer orders but increase the average order value at the same time so the two effects neutralise each other and the revenue per user stays intact.

Situations where the treatment changes the variance of the event outcome, leaving the average unaffected. For example, the treatment can increase the variability of the order values without changing their average.

If in a given practical application, having sensitivity to one of the scenarios above is highly undesirable, it is safer to adhere to alternative sequential testing methods (e.g. [9, 10]). We consider extending the proposed method to cover situations of those types as a topic for future research.

Note that none of the problematic two scenarios can materialise when the event outcome is constant (i.e. the metric of interest simply counts events). In addition, the first scenario cannot hold when the treatment cannot affect the number of events, for example, when the events correspond to incoming patients in a medical study.

From a theoretical perspective, the amount of oversensitivity of the proposed method in the above two situations would depend on how much the median of the “residual sum” (or the sum of the remaining increments until the end of monitoring) deviates from

zero. Intuitively, in the early steps of monitoring, this should not be a problem because the number of remaining increments is large and their sum's distribution would be approximately symmetric due to the Central Limit Theorem. Yet, closer to the end of monitoring, this deviation can be considerable. Mitigation strategies can include stopping the monitoring early or setting the threshold as if the monitoring is to be run for longer than in reality. The effectiveness of those mitigation strategies and the tradeoff with the power would depend on how quickly the distribution of increment sums converges to a normal distribution. Overall, we see studying the behaviour of our proposed method in situations mentioned in this section and seeking mitigation strategies as a large topic for future research.

It is worth emphasising that in some situations it can be desirable to capture all relevant potential defects (beyond the effect on the mean) [20]. For example, an increased outcome variance can indicate that the effect of the treatment is heterogeneous and some important subgroups of the population can be negatively affected (even though the overall mean stays the same). In such scenarios, the extra sensitivity mentioned in this section is not really a limitation but an advantage instead.

9 CONCLUSION

Motivated by practical challenges that undermine the adoption of sequential testing procedures, this paper proposes a simple yet powerful method for constructing confidence boundaries that permit continuous monitoring of online experiments - both for discrete and continuous variables. It has no tuning parameters and all of its inputs can be straightforwardly estimated from pre-experiment data, which makes it easy to adopt. The method's effectiveness is demonstrated both in simulations and using real-world data. We hope the proposed method will enable wider use of sequential testing in practice, increasing the speed of experimentation and lowering its cost.

REFERENCES

- [1] Jonah B. Gelbach, A. Colin Cameron, and Douglas L. Miller. 2011. Robust Inference With Multiway Clustering. *Journal of Business & Economic Statistics* 29, 2 (2011), 238–249. <https://doi.org/10.1198/jbes.2010.07136> arXiv:<https://doi.org/10.1198/jbes.2010.07136>
- [2] Peter Armitage et al. 1954. Sequential tests in prophylactic and therapeutic trials. *Quarterly Journal of Medicine* 23, 91 (1954), 255–74.
- [3] Aurélien F. Bibaut, Nathan Kallus, and Michael Lindon. 2022. Near-Optimal Non-Parametric Sequential Tests and Confidence Sequences with Possibly Dependent Observations. <https://api.semanticscholar.org/CorpusID:255341081>
- [4] I Bross. 1952. Sequential medical plans. *Biometrics* 8, 3 (1952), 188–205.
- [5] Harold French Dodge and Harry G Romig. 1929. A method of sampling inspection. *The Bell System Technical Journal* 8, 4 (1929), 613–631.
- [6] J.L. Doob. 1953. *Stochastic Processes*. Wiley. <https://books.google.de/books?id=KvJQAAAAMAAJ>
- [7] Erik Drysdale. 2021. The sum of a normal and a truncated normal. Blog Post. <https://www.erikdrysdale.com/NTS/>
- [8] K. K. Gordon Lan and David L. Demets. 1983. Discrete sequential boundaries for clinical trials. *Biometrika* 70, 3 (12 1983), 659–663. <https://doi.org/10.1093/biomet/70.3.659> arXiv:<https://academic.oup.com/biomet/article-pdf/70/3/659/686493/70-3-659.pdf>
- [9] Dae Woong Ham, Iavor Bojinov, Michael Lindon, and Martin Tingley. 2023. Design-Based Confidence Sequences: A General Approach to Risk Mitigation in Online Experimentation. arXiv:2210.08639 [stat.ME]
- [10] Steven R. Howard, Aaditya Ramdas, Jon McAuliffe, and Jasjeet Sekhon. 2021. Time-uniform, nonparametric, nonasymptotic confidence sequences. *The Annals of Statistics* 49, 2 (apr 2021). <https://doi.org/10.1214/20-aos1991>
- [11] Kevin Jamieson and Lalit Jain. 2018. A Bandit Approach to Multiple Testing with False Discovery Control. In *Proceedings of the 32nd International Conference on Neural Information Processing Systems (NIPS'18)*. Curran Associates Inc., Red Hook, NY, USA, 3664–3674.
- [12] Kevin Jamieson, Matthew Malloy, Robert Nowak, and Sébastien Bubeck. 2013. lil' UCB : An Optimal Exploration Algorithm for Multi-Armed Bandits. arXiv:1312.7308 [stat.ML]
- [13] Ramesh Johari, Pete Koomen, Leonid Pekelis, and David Walsh. 2022. Always valid inference: Continuous monitoring of a/b tests. *Operations Research* 70, 3 (2022), 1806–1821.
- [14] Emilie Kaufmann, Olivier Cappé, and Aurélien Garivier. 2016. On the complexity of best arm identification in multi-armed bandit models. *Journal of Machine Learning Research* 17 (2016), 1–42.
- [15] Hea-Jung Kim. 2006. On the Distribution and Its Properties of the Sum of a Normal and a Doubly Truncated Normal. *The Korean Communications in Statistics* (2006).
- [16] Alexey Kurennoy and Tural Gurbanov. 2024. YEAST: YET Another Sequential Test. Git Repository. <https://github.com/akurennoy/yeast.git> This paper's code companion.
- [17] Nicholas Larsen, Jonathan Stallrich, Srijan Sengupta, Alex Deng, Ron Kohavi, and Nathaniel Stevens. 2023. Statistical Challenges in Online Controlled Experiments: A Review of A/B Testing Methodology. arXiv:2212.11366 [stat.AP]
- [18] Michael Lindon, Dae Woong Ham, Martin P. Tingley, and Iavor Bojinov. 2022. Anytime-Valid Linear Models and Regression Adjusted Causal Inference in Randomized Experiments. <https://api.semanticscholar.org/CorpusID:259309472>
- [19] Michael Lindon and Alan Malek. 2022. Anytime-Valid Inference For Multinomial Count Data. In *Advances in Neural Information Processing Systems*, S. Koyejo, S. Mohamed, A. Agarwal, D. Belgrave, K. Cho, and A. Oh (Eds.), Vol. 35. Curran Associates, Inc., 2817–2831. https://proceedings.neurips.cc/paper_files/paper/2022/file/12f3bd5d2b7d93eadc1bf508a0872dc2-Paper-Conference.pdf
- [20] Michael Lindon, Chris Sanden, and Vaché Shirikian. 2022. Rapid Regression Detection in Software Deployments through Sequential Testing. In *Proceedings of the 28th ACM SIGKDD Conference on Knowledge Discovery and Data Mining (Washington DC, USA) (KDD '22)*. Association for Computing Machinery, New York, NY, USA, 3336–3346. <https://doi.org/10.1145/3534678.3539099>
- [21] M. Loeve. 1960. *Probability Theory. 2nd Edition*. D. Van Nostrand Company Inc.
- [22] Evan Miller. 2015. Simple Sequential A/B Testing. Blog Post. <https://www.evanmiller.org/sequential-ab-testing.html>
- [23] Peter C. O'Brien and Thomas R. Fleming. 1979. A Multiple Testing Procedure for Clinical Trials. *Biometrics* 35, 3 (1979), 549–556. <http://www.jstor.org/stable/2530245>
- [24] Stuart J. Pocock. 1977. Group Sequential Methods in the Design and Analysis of Clinical Trials. *Biometrika* 64, 2 (1977), 191–199. <http://www.jstor.org/stable/2335684>
- [25] Herbert Robbins. 1970. Statistical Methods Related to the Law of the Iterated Logarithm. *The Annals of Mathematical Statistics* 41, 5 (1970), 1397 – 1409. <https://doi.org/10.1214/aoms/1177696786>
- [26] Márten Schultzberg and Sebastian Ankargren. 2023. Choosing a Sequential Testing Framework – Comparisons and Discussions. Blog Post. <https://engineering.atspotify.com/2023/03/choosing-sequential-testing-framework-comparisons-and-discussions/>
- [27] Márten Schultzberg and Sebastian Ankargren. 2023. Simulation files for Schultzberg & Ankargren blogpost 2023. GitHub repository. <https://github.com/MSchultzberg/SeqTestBlog>
- [28] Eric V. Slud and L. J. Wei. 1982. Two-Sample Repeated Significance Tests Based on the Modified Wilcoxon Statistic. *J. Amer. Statist. Assoc.* 77 (1982), 862–868. <https://api.semanticscholar.org/CorpusID:121593359>
- [29] STATSIG. 2023. Sequential Testing. Documentation. <https://docs.statsig.com/experiments-plus/sequential-testing>
- [30] A.W. van der Vaart. 2000. *Asymptotic Statistics*. Cambridge University Press. <https://books.google.ie/books?id=SYImEAAQBAJ>
- [31] A. Wald. 1945. Sequential Tests of Statistical Hypotheses. *The Annals of Mathematical Statistics* 16, 2 (1945), 117 – 186. <https://doi.org/10.1214/aoms/1177731118>
- [32] A. Wald. 1947. *Sequential analysis*. Wiley. <https://books.google.de/books?id=0nREAAAIAAJ>
- [33] G. Wassmer and W. Brannath. 2016. *Group Sequential and Confirmatory Adaptive Designs in Clinical Trials*. Springer International Publishing. <https://books.google.ie/books?id=hT2IDAAAQBAJ>
- [34] H. White. 1984. *Asymptotic Theory for Econometricians*. Elsevier Science. <https://books.google.ie/books?id=hSu7AAAAIAAJ>
- [35] Fanny Yang, Aaditya Ramdas, Kevin Jamieson, and Martin Wainwright. 2017. A Framework for Multi-A(Rmed)/B(Andit) Testing with Online FDR Control. In *Proceedings of the 31st International Conference on Neural Information Processing Systems (NIPS'17)*. Curran Associates Inc., Red Hook, NY, USA, 5959–5968.
- [36] Achim Zeileis. 2004. Econometric Computing with HC and HAC Covariance Matrix Estimators. *Journal of Statistical Software* 11, 10 (2004), 1–17. <https://doi.org/10.18637/jss.v011.i10>
- [37] Achim Zeileis, Susanne Köll, and Nathaniel Graham. 2020. Various Versatile Variances: An Object-Oriented Implementation of Clustered Covariances in R. *Journal of Statistical Software* 95, 1 (2020), 1–36. <https://doi.org/10.18637/jss.v095.i01>

APPENDIX

A PROOFS AND AUXILIARY STATEMENTS

LEMMA 1. Let $Y_i: \Omega \mapsto \mathbb{R}$ and $W_i: \Omega \mapsto \{0, 1\}$, $i = 1, \dots, N$, be random variables, and let S_n , $n \geq 1$, be the running sum defined by (1)–(2). Suppose that Assumption 1 and the null hypothesis (3)–(4) hold.

Then for any $N \geq 1$ and any $k = 1, \dots, N$ the distribution of $S_N - S_k$ conditional on S_1, \dots, S_k is symmetric around 0.

PROOF. Fix any $N \geq 2$ and any $k = 1, \dots, N - 1$ (for $N = 1$ or $k = N$ the statement is trivial). Let $\mathcal{T} = \{-1, +1\}^{N-k}$ be the set of all possible combinations of -1 and $+1$ of length $N - k$. Furthermore, for any $\tau \in \mathcal{T}$, let $\bar{\tau} \in \mathcal{T}$ be the combination obtained by negating every element of τ , i. e. $\bar{\tau}_j = -\tau_j$ for all $j = 1, \dots, N - k$. Next, define

$$A_\tau = \{1 - 2W_i = \tau_{i-k} \forall i = k + 1, \dots, N\}, \quad \tau \in \mathcal{T}.$$

Note that

$$A_\tau \cap A_{\tau'} = \emptyset \forall \tau, \tau' \in \mathcal{T} \text{ and } \cup_{\tau \in \mathcal{T}} A_\tau = \cup_{\tau \in \mathcal{T}} A_{\bar{\tau}} = \Omega. \quad (10)$$

Also, Assumption 1 together with the null hypothesis imply that

$$\Pr(A_\tau) = \Pr(A_{\bar{\tau}}) \quad \forall \tau \in \mathcal{T}. \quad (11)$$

Finally, fix an arbitrary Borel set $Q \subset \mathbb{R}$ and set

$$B = \{S_N - S_k \in Q\}, \quad \bar{B} = \{S_k - S_N \in Q\}.$$

Denoting the conditional probability $\Pr(\cdot \mid S_1, \dots, S_k)$ by \Pr_k , we will now derive the key relationship for the proof of the lemma. Specifically, (3) and (11) imply that for any $\tau \in \mathcal{T}$ we have

$$\begin{aligned} \Pr_k(\bar{B} \cap A_\tau) &= \Pr_k \left(\left\{ - \sum_{i=k+1}^N \tau_{i-k} Y_i \in Q \right\} \cap A_\tau \right) \stackrel{(3)}{=} \\ &\stackrel{(3)}{=} \Pr_k \left\{ - \sum_{i=k+1}^N \tau_{i-k} Y_i \in Q \right\} \Pr_k(A_\tau) \stackrel{(11)}{=} \\ &\stackrel{(11)}{=} \Pr_k \left\{ - \sum_{i=k+1}^N \tau_{i-k} Y_i \in Q \right\} \Pr_k(A_{\bar{\tau}}) = \\ &= \Pr_k \left\{ \sum_{i=k+1}^N \bar{\tau}_{i-k} Y_i \in Q \right\} \Pr_k(A_{\bar{\tau}}) \stackrel{(3)}{=} \\ &\stackrel{(3)}{=} \Pr_k \left(\left\{ \sum_{i=k+1}^N \bar{\tau}_{i-k} Y_i \in Q \right\} \cap A_{\bar{\tau}} \right) = \Pr_k(B \cap A_{\bar{\tau}}) \end{aligned} \quad (12)$$

From (12) and (10), it follows that

$$\begin{aligned} \Pr_k(\bar{B}) &\stackrel{(10)}{=} \sum_{\tau \in \mathcal{T}} \Pr_k(\bar{B} \cap A_\tau) \stackrel{(12)}{=} \\ &\stackrel{(12)}{=} \sum_{\tau \in \mathcal{T}} \Pr_k(B \cap A_{\bar{\tau}}) \stackrel{(10)}{=} \Pr_k(B) \end{aligned} \quad (13)$$

Since the fixed Borel set Q was arbitrary, (13) proves that conditionally on S_1, \dots, S_k , the distribution of $S_N - S_k$ and $S_k - S_N$ is the same or, equivalently, the distribution of $S_N - S_k$ is symmetric about zero. \square

LEMMA 2. Suppose that the assumptions of Lemma 1 hold.

Then for any $N \geq 1$ and any $b > 0$, we have

$$\Pr \left\{ \max_{n=1}^N S_n \geq b \right\} \leq 2 \Pr\{S_N \geq b\}, \quad (14)$$

and

$$\Pr \left\{ \max_{n=1}^N |S_n| \geq b \right\} \leq 2 \Pr\{|S_N| \geq b\}. \quad (15)$$

PROOF. From Lemma 1, it follows that for any $k = 1, \dots, N$, the distribution of $S_N - S_k$ conditional on S_1, \dots, S_k is symmetric about 0 and therefore the conditional median $\mu(S_N - S_k \mid S_1, \dots, S_k)$ is zero. Then (14) and (15) easily follow from the generalised Levy's inequalities [21, Paragraph 29.1, A]. \square

PROOF OF THEOREM 1. Fix an arbitrary $\alpha \in [0, 1]$ and $\varepsilon > 0$.

By the continuity of Φ , there exists a sufficiently small $\delta > 0$ such that

$$\left| \Phi(z_{1-\alpha/2}) - \Phi(z_{1-\alpha/2} - \delta) \right| \leq \frac{\varepsilon}{4}. \quad (16)$$

Furthermore, the null hypothesis implies that

$$E[X_i] = E[(1 - 2W_i)Y_i] \stackrel{(3)}{=} (1 - 2\Pr\{W_i = 1\})E[Y_i] \stackrel{(4)}{=} 0$$

for all $i \geq 1$. Therefore, $E[S_N] = 0$ for all $N \geq 1$ and by the Central Limit Theorem we have that there exists $N_{\alpha, \varepsilon} \geq 1$ such that

$$\left| \Pr \left\{ S_N / \sqrt{\text{var}(S_N)} \leq z_{1-\alpha/2} - \delta \right\} - \Phi(z_{1-\alpha/2} - \delta) \right| \leq \frac{\varepsilon}{4} \quad (17)$$

for all $N \geq N_{\alpha, \varepsilon}$. Together with (14), relations (16)–(17) give

$$\begin{aligned} \Pr \left\{ \max_{n=1}^N S_n > z_{1-\alpha/2} \sqrt{N \text{var}(S_N)} \right\} &= \\ &= \Pr \left\{ \max_{n=1}^N S_n > z_{1-\alpha/2} \sqrt{\text{var}(S_N)} \right\} \leq \\ &\leq \Pr \left\{ \max_{n=1}^N S_n \geq z_{1-\alpha/2} \sqrt{\text{var}(S_N)} \right\} \stackrel{(14)}{\leq} \\ &\stackrel{(14)}{\leq} 2 \Pr \left\{ S_N \geq z_{1-\alpha/2} \sqrt{\text{var}(S_N)} \right\} = \\ &= 2 \Pr \left\{ S_N / \sqrt{\text{var}(S_N)} \geq z_{1-\alpha/2} \right\} \leq \\ &\leq 2 \Pr \left\{ S_N / \sqrt{\text{var}(S_N)} > z_{1-\alpha/2} - \delta \right\} = \\ &= 2 \left(1 - \Pr \left\{ S_N / \sqrt{\text{var}(S_N)} \leq z_{1-\alpha/2} - \delta \right\} \right) = \\ &= 2 \left(1 - \Phi(z_{1-\alpha/2}) \right) + \\ &+ 2 \left(\Phi(z_{1-\alpha/2}) - \Phi(z_{1-\alpha/2} - \delta) \right) + \\ &+ 2 \left(\Phi(z_{1-\alpha/2} - \delta) - \Pr \left\{ S_N / \sqrt{\text{var}(S_N)} \leq z_{1-\alpha/2} - \delta \right\} \right) \stackrel{(16),(17)}{\leq} \\ &\stackrel{(16),(17)}{\leq} \alpha + \frac{\varepsilon}{2} + \frac{\varepsilon}{2} = \alpha + \varepsilon \end{aligned}$$

for all $N \geq N_{\alpha, \varepsilon}$. This completes the proof. \square

PROOF OF THEOREM 2. Denote $m_N = \sum_{i=1}^N \mu_i$ and let ξ_N stand for the centered and standardised sum $(S_N - N\mu) / \sqrt{\text{var}(S_N)}$. By the Central Limit Theorem $\xi_N \xrightarrow{d} \mathcal{N}(0, 1)$ and therefore ξ_N is stochastically bounded (see, for example, [30, Theorem 2.4]).

Now, fix an arbitrary $\varepsilon > 0$. From the stochastic boundedness of ξ_N and V_N , it follows that there exist M_1 and M_2 such that for all sufficiently large N we have

$$\Pr \{|\xi_N| \leq M_1\} \geq 1 - \frac{\varepsilon}{2} \quad (18)$$

and

$$\Pr \{|V_N| \leq M_2\} \geq 1 - \frac{\varepsilon}{2}. \quad (19)$$

From (18)–(19), it follows that

$$\Pr \left\{ \xi_N + m_N \sqrt{N} / \sqrt{V_N} \geq -M_1 + m_N \sqrt{N} / \sqrt{M_2} \right\} \geq 1 - \varepsilon$$

for all large enough N . But then for any sufficiently large N , we have that

$$\Pr \left\{ \xi_N + m_N \sqrt{N} / \sqrt{V_N} > z_{1-\alpha/2} \right\} \geq 1 - \varepsilon. \quad (20)$$

because $(-M_1 + m_N \sqrt{N} / \sqrt{M_2}) \rightarrow \infty$ as $N \rightarrow \infty$. Then we can derive that

$$\begin{aligned} \Pr \left\{ \max_{n=1}^N S_n > z_{1-\alpha/2} \sqrt{NV_N} \right\} &\geq \Pr \left\{ S_N > z_{1-\alpha/2} \sqrt{NV_N} \right\} = \\ &= \Pr \left\{ \xi_N + m_N \sqrt{N} / \sqrt{V_N} > z_{1-\alpha/2} \right\} \stackrel{(20)}{\geq} 1 - \varepsilon \end{aligned}$$

for all sufficiently large N . Since ε was arbitrary, this completes the proof. \square

B ADDITIONAL EVALUATIONS

In this appendix, we report additional evaluation results for the case where the evaluated methods (see the list in Section 5) were employed in the discrete mode (i. e. with only a fixed number of interim checks). The evaluation were performed against the same replications as in our main experiment in Section 5. We again follow the protocol from [26] and perform 14, 28, 42, and 56 significance checks (spaced equally across the timeline). Since in these evaluations, we operate in a discrete setting, we were able to include the discrete baselines from [26] in the comparison. Namely, we additionally compare against the following method.

GST The group sequential test with alpha spending as proposed in [8]. The test performs a significance check after the arrival of each batch of observations. To schedule a prespecified number of checks it therefore needs an estimate of the total number of observations that would be collected during the experiment time frame. In the evaluations, we consider three different scenarios: when the sample size is estimated precisely (right number of checks), when the sample size is underestimated (leading to more checks than planned), and when the sample size is overestimated (leading to making fewer checks than planned). The respective entries in the evaluation table are referred to as *GST*, *GSToversampled*, and *GSTundersampled*, respectively. The actual sample size was 500 and the respective sample size estimates for the three scenarios were 500, 250, and 750. In the case of oversampling (i. e. the sample size is underestimated), we apply the correction to the bounds proposed in [33, pp. 78–79]. We consider quadratic and cubic alpha-spending, the latter having the “phi3” prefix in the name.

We report the share of replications where the test detects an effect (i. e. the significance is detected in at least one of the interim

checks). Table 5 (“False Positive Rate”) reports this share for the case where no actual effect was present. All of the compared methods except CAA and oversampled versions of GST keep the false detection rate below the nominal level of 5%. Table 6 (“Power”) contains the share of replications with a detection for the case where the treatment effect was set to 0.2 standard deviations. The methods with an inflated false detection rate were excluded from the power comparisons. The GST method with cubic alpha-spending demonstrated the highest power, closely followed by SST (the method proposed in Section 3), and GST with quadratic alpha-spending. We find it remarkable that our proposed method, despite supporting continuous monitoring, performed on par with the GST method in the discrete monitoring setting.

Table 5: False Positive Rate

type	14	28	42	56
1 YEAST	0.04	0.04	0.04	0.04
2 pYEAST7	0.02	0.03	0.03	0.03
3 pYEAST14	0.02	0.02	0.02	0.02
4 GST	0.05	0.05	0.05	0.05
5 GSTphi3	0.05	0.05	0.05	0.05
6 GSToversampled	0.07	0.07	0.07	0.08
7 GSToversampledphi3	0.09	0.10	0.10	0.07
8 GSTundersampled	0.03	0.02	0.03	0.03
9 GSTundersampledphi3	0.01	0.01	0.01	0.01
10 mSPRTphi100	0.01	0.01	0.01	0.01
11 mSPRTphi11	0.01	0.02	0.02	0.02
12 mSPRTphi25	0.01	0.02	0.02	0.02
13 GAVI250	0.01	0.02	0.02	0.02
14 GAVI500	0.01	0.01	0.01	0.01
15 GAVI750	0.01	0.01	0.01	0.01
16 CAA	0.06	0.06	0.07	0.07
17 Bonferroni	0.01	0.01	0.01	0.01

Table 6: Power (under a treatment effect of 0.2 standard deviations)

type	14	28	42	56	stream
1 YEAST	0.90	0.91	0.91	0.91	0.92
2 pYEAST7	0.79	0.80	0.81	0.81	0.82
3 pYEAST14	0.75	0.76	0.76	0.77	0.78
4 GST	0.90	0.90	0.90	0.89	-
5 GSTphi3	0.93	0.92	0.93	0.93	-
6 GSTundersampled	0.83	0.82	0.82	0.82	-
7 GSTundersampledphi3	0.72	0.71	0.71	0.71	-
8 mSPRTphi100	0.71	0.73	0.73	0.74	0.76
9 mSPRTphi11	0.68	0.70	0.70	0.71	0.73
10 mSPRTphi25	0.71	0.72	0.73	0.74	0.76
11 GAVI250	0.72	0.73	0.74	0.75	0.76
12 GAVI500	0.72	0.73	0.74	0.74	0.76
13 GAVI750	0.71	0.72	0.73	0.73	0.75
14 Bonferroni	0.55	0.53	0.51	0.50	0.40